NOWDiagnostics’ First To Know has FDA De Novo marketing authorization as a new test for syphilis. The at-home product needs only a single drop of blood to test for this sexually transmitted infection.
Thermo Fisher Scientific’s acquisition of The Binding Site brings a company that specializes in diagnostic tests for blood cancers and immune system disorders. It’s Thermo Fisher’s biggest acquisition since its 2021 buyout of contract research organization PPD.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The current pandemic, which has caused treatment delays, is simply another reason that home-based treatment options should become more readily available to cancer patients.
Here's a look at a company that could seriously be in the running for Theranos' biggest competitor.
NOWDiagnostics CEO Kevin Clark shares about the company's single fingertip-prick blood testing that could change the way we diagnose diseases as well as detect pregnancy.